PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 28, 2026Kidney International Reports0 citationsOpen Access

Wcn26-9116 Efficacy of Pegcetacoplan in Patients With Lower Baseline Proteinuria: A Subgroup Analysis From the Valiant Trial

SHSeung Hyeok HanHKH J KangNWNicholas Webb

Key Result

Pegcetacoplan treatment for 52 weeks demonstrated consistent clinical efficacy and sustained benefit in adolescents, matching the overall VALIANT trial population.

Key Points

  • The study aims to evaluate the efficacy of pegcetacoplan in patients with lower baseline proteinuria.
  • Conducted a subgroup analysis from the VALIANT trial.
  • Evaluated clinical efficacy over a 52-week treatment period.
  • Included adolescents as a specific focus group.
  • Efficacy of pegcetacoplan was consistent with the overall VALIANT population.
  • Demonstrated sustained benefits over 52 weeks in treated adolescents.

Structured PICO

Does pegcetacoplan reduce proteinuria in patients with C3G and IC-MPGN with lower baseline proteinuria?

P
Population
Patients with C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) with baseline proteinuria ≤1.5 g/g
I
Intervention
Pegcetacoplan (subcutaneous infusion twice weekly)
C
Comparator
Placebo
O
Outcome
Change from baseline to Week 26 in log-transformed urine protein-to-creatinine ratio (UPCR) and estimated glomerular filtration rate (eGFR)surrogate

Pegcetacoplan demonstrated clinically meaningful reductions in proteinuria in patients with C3G and IC-MPGN with lower baseline proteinuria (≤1.5 g/g).

Limitations

  • Post hoc analysis

Abstract

Conclusion: Clinical efficacy of 52 weeks of pegcetacoplan treatment for adolescents was consistent with the overall population of VALIANT, confirming its sustained benefit in broad patient populations.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Han et al. (2026) studied this question. Pegcetacoplan treatment for 52 weeks demonstrated consistent clinical efficacy and sustained benefit in adolescents, matching the overall VALIANT trial population.

synapsesocial.com/papers/69c770418bbfbc51511e0723https://doi.org/10.1016/j.ekir.2026.106328
Ask AI
Helpful
Bookmark
Share
View Full Paper